Skip to main content
. 2024 Dec 30;19:495. doi: 10.1186/s13023-024-03474-6

Fig. 4.

Fig. 4

Serious adverse events (SAEs) in part 1 (week 12), part 2 (week 48), and part 3 (EW 196). The numbers on the X-axis are the number of patients who withdrew due to SAEs in the respective studies and groups. Three patients from the placebo group in part 1, two patients from the placebo group, and four from the Omav group in part 2 withdrew from the study. None of the participants withdrew from part 3 due to SAEs